相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial
Michael P. Whyte et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia
Hae Il Cheong et al.
JBMR PLUS (2019)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis
Karl L. Insogna et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Burosumab Therapy in Children with X-Linked Hypophosphatemia
Thomas O. Carpenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hypertension is a characteristic complication of X-linked hypophosphatemia
Yoshie Nakamura et al.
ENDOCRINE JOURNAL (2017)
Pharmacokinetics and Pharmacodynamics of a Human Monoclonal Anti-FGF23 Antibody (KRN23) in the First Multiple Ascending-Dose Trial Treating Adults With X-Linked Hypophosphatemia
Xiaoping Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Incidence and prevalence of nutritional and hereditary rickets in southern Denmark
Signe Sparre Beck-Nielsen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Klotho converts canonical FGF receptor into a specific receptor for FGF23
Itaru Urakawa et al.
NATURE (2006)
Hypertension in hypophosphatemic rickets - role of secondary hyperparathyroidism
US Alon et al.
PEDIATRIC NEPHROLOGY (2003)
分享论文
